Aesica Concentrates Investment in Lucrative German Formulations Business
News Jul 12, 2014
Aesica Pharmaceuticals is adding additional services in its oral solids capability including a new roller compaction unit for dry granulation production in Zwickau, Germany after identifying this area as a key growth market within the domestic market.
The company is committed to capitalizing on the presence of its German sites (Monheim and Zwickau), having identified the German pharma economy as a growth area for its services and is planning to take an increasing share of the market.
This latest investment compliments other recent investments in the region, including a new tablet coater capability and pouch packing line, enhancing a diverse range of capabilities it has within the country.
The new roller compaction unit uses a continuous production step that enhances product uniformity and has been undertaken following a market demand for pharmaceutical formulation technologies that enable the formulation of APIs otherwise inhibited by the presence of water.
Ian Muir, Managing Director, Finished Dose at Aesica commented: “This new investment aligns with our strategy of investing in our German sites to broaden capabilities, which is expanding our domestic market share within Germany, whilst allowing us to offer new services to our global customers. The dry granulation capability will drive business growth as customers with moisture sensitive APIs seek appropriate technologies, and crucially, experienced CDMOs that can deliver their products”.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE